Numeta G13%e (Valine, Ornithine Hydrochloride, Alanine, Arginine, Cysteine, Histidine, Isoleucine, Leucine, Methio)

The mixture supplies a balanced profile of amino acids that serve as building blocks for protein synthesis, replenish nitrogen stores, and support metabolic processes like tissue repair and immune function. Delivered directly into the bloodstream, it bypasses the digestive system, ensuring rapid availability for patients with compromised gastrointestinal absorption.

The dose of Numeta G13%e is individualized by the prescribing clinician based on the patient’s weight, clinical condition, renal and hepatic function, and overall nutritional goals. Healthcare professionals calculate the infusion rate to meet specific protein and nitrogen requirements.

Use of Numeta G13%e during pregnancy or lactation should be considered only if clearly needed and after evaluating potential benefits versus risks. The prescribing physician should assess maternal and fetal health, as amino acid requirements may differ, and monitor both mother and infant closely.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if required), and necessary import documentation.

Numeta G13%e offers a comprehensive blend of essential and non‑essential amino acids in a formulation designed for balanced nitrogen delivery. Compared with older single‑amino‑acid solutions, it reduces the need for multiple infusions and helps maintain a more physiological amino acid profile, potentially improving metabolic stability and patient outcomes.

The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen. Before use, inspect the vial for any particulate matter or discoloration, and allow it to reach room temperature if required by the administration protocol, following aseptic handling procedures.

Numeta G13%e is administered intravenously, typically via a peripheral or central venous catheter. The infusion rate is set according to the clinician’s prescription, and the solution is diluted in compatible IV fluids as directed. Continuous monitoring of vital signs and laboratory parameters is recommended during the infusion.

Serious risks include anaphylactic reactions, severe electrolyte imbalances (such as hyperkalemia or hypernatremia), renal dysfunction, and hyperammonemia, especially in patients with liver impairment. Prompt recognition and management of these events are essential, and patients should be closely monitored throughout therapy.

Numeta G13%e should be avoided in individuals with known hypersensitivity to any of its amino acid components, in patients with uncontrolled severe electrolyte disturbances, and in those with acute hepatic failure where amino acid metabolism is markedly impaired. Clinical judgment is required for each case.